Welcome to our dedicated page for Astrana Health SEC filings (Ticker: ASTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astrana Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astrana Health's regulatory disclosures and financial reporting.
Astrana Health, Inc. reported strong first quarter 2026 results, with total revenue of $965,100 (thousands), up 56% from the prior-year quarter. Net income attributable to Astrana was $14,436 (thousands), and diluted EPS doubled to $0.29.
Non-GAAP performance also improved, as Adjusted EBITDA rose to $66,298 (thousands), a year-over-year increase of 82%, and Adjusted EPS – diluted reached $0.74. Free cash flow increased to $64,056 (thousands), up 372% year over year, while cash and cash equivalents grew to $478,383 (thousands).
The company reaffirmed 2026 guidance, targeting total revenue between $3,800,000 and $4,100,000 (thousands), Adjusted EBITDA between $250,000 and $280,000 (thousands), and free cash flow between $105,000 and $132,500 (thousands). Management highlighted growth in full-risk value-based arrangements and continued deployment of its AI-enabled care platform.
Astrana Health, Inc. is holding its 2026 Annual Meeting on June 10, 2026 to vote on four key items: electing nine directors, ratifying Ernst & Young LLP as auditor, approving an advisory say-on-pay vote, and expanding its 2024 Equity Incentive Plan.
The equity plan amendment would increase the shares of common stock reserved for issuance from 4,100,000 to 5,100,000 and extend the plan’s term. As of the April 14, 2026 record date, Astrana had 55,713,532 common shares outstanding, and its largest stockholder, APC, held 6,132,802 shares, subject to a 9.99% voting cap.
Astrana Health, Inc. COO and CFO Basho Chandan surrendered 3,870 shares of common stock at $29.07 per share on April 14, 2026 to cover tax withholding obligations on newly vested restricted stock. After this tax-withholding disposition, he directly holds 167,765 shares, including 30,404 unvested restricted shares and additional restricted stock units scheduled to vest through 2027.
Lam Thomas S. reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. director Thomas S. Lam received an equity award of 41,667 restricted stock units (RSUs) of common stock on April 6, 2026. The RSUs carry no purchase price and represent a compensation grant, not an open-market share purchase.
Each RSU is a contingent right to one Astrana common share. The award will vest in eight equal semi-annual installments beginning on October 6, 2026, provided Lam remains employed with Astrana Health and/or its affiliates. After this grant, he directly holds 465,657 shares of common stock, including other previously granted restricted stock and RSUs subject to multi-year vesting schedules.
Separate from his direct holdings, Lam is reported as having indirect interests in 6,132,802 shares held by Allied Physicians of California, a Professional Medical Corporation, where he serves as CEO, CFO, director and stockholder, and 1,133,706 shares held by the Thomas and Jeanette Lam 2002 Family Trust. He disclaims beneficial ownership of the Allied Physicians shares except to the extent of his pecuniary interest.
Sim Kenneth T. reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. Executive Chairman Kenneth T. Sim received a grant of 100,000 restricted stock units of common stock as compensation. Each unit represents one share and vests in eight equal semi-annual installments beginning on October 6, 2026, if he remains employed. After this award, he directly holds 739,407 common shares, including other unvested restricted stock and restricted stock units with vesting schedules extending into 2027. He also has additional indirect holdings through various trusts and entities where he disclaims full beneficial ownership.
Sim Brandon reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. CEO and President Brandon Sim reported an equity compensation grant in the form of 201,056 restricted stock units, each representing a right to receive one share of common stock. These units are scheduled to vest in eight equal semi-annual installments beginning on October 6, 2026, subject to continued employment. Following this grant, Sim directly holds 1,246,385 shares of common stock, including other unvested restricted stock and restricted stock units. The filing also notes indirect holdings in the Sim Family Irrevocable Trust 2021 and the Brandon Sim 2020 Irrevocable Trust, for which Sim disclaims beneficial ownership except for any pecuniary interest.
Astrana Health Chief Medical Officer Dinesh M. Kumar reported routine equity compensation activity. On April 1, 2026, he received 35,300 shares of common stock at no cost upon vesting of performance-based restricted stock units after performance exceeded target levels. On the same date, 57,980 shares were surrendered at $24.51 per share to cover tax withholding obligations tied to vesting restricted stock and restricted stock units, rather than being sold on the open market. After these transactions, he directly held 177,655 shares, including time-based restricted stock and restricted stock units scheduled to vest through January 2027 and in six semi-annual installments beginning September 5, 2026, as well as shares acquired under the employee stock purchase plan.
Astrana Health, Inc. COO and CFO Basho Chandan reported a small tax-related share disposition. On April 2, 2026, he surrendered 2,092 shares of common stock at an assigned price of $25.05 per share to cover tax withholding obligations tied to restricted stock units that vested that day.
After this tax-withholding transaction, Chandan directly holds 171,635 shares of Astrana Health common stock. This figure includes unvested restricted stock and restricted stock units scheduled to vest over the next several years, subject to his continued employment with the company.
Astrana Health, Inc. filed an 8-K providing interim unaudited financial statements for PHP Holdings, LLC & Rhode Island Market and unaudited pro forma results reflecting Astrana’s acquisition of this business.
For the nine months ended June 30, 2025, the acquired business generated $961.8 million in net revenue, primarily from capitation of $830.4 million, but reported a net loss of $38.7 million. Total assets were $336.5 million and total liabilities $1.57 billion, including $1.26 billion of debt and $75.3 million of redeemable convertible preferred stock, resulting in a significant members’ deficit.
The notes explain PHP Holdings’ highly capitated model, major credit facilities such as the PhysicianCo Term Loan and Phase I Convertible Note, and confirm Astrana closed the acquisition of Alta Newport Hospital, Prospect Health Plan and related assets for $674.9 million on July 1, 2025.